Ann: Appendix 4E and Annual Report to Shareholders, page-23

Yeah, what are we going to do as investors? Selling here is stupid frankly.

Management have shown themselves to be tardy again. Its nothing new. A -10% sell down is ridiculous, but that's the market. In the context of a 7 year investment they are still FDA/EMA/TGA approved in CelGro Bone. They are likely to be similarly approved in CelGro Nerve within the next year. Revenues are growing at 40% in a COVID stricken time period. This company is far better placed than it was a year ago.

I get entirely investors getting peed off at management, but nothing in these results to say success will not come, as per usual with OCC and bio-tech generally it will be 3 - 6 months later than guided.

They are one the verge of a potential J&J partnership. This is a massive share price signal of loss of confidence in management. If you are still long-term a believer in the products you simply ride the storm today or you lock in a loss when the company is ultimately very well placed on regulatory and commercial success.